A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)

CONCLUSIONS: Pepinemab (20 mg/kg) is safe, well tolerated and resulted in adequate and sustained target saturation in pediatric patients. Encouraging disease control in two patients with osteosarcoma warrants further investigation with novel combination strategies to modulate the tumor microenvironment and antitumor immune response.CLINICAL TRIAL REGISTRY: This trial is registered as NCT03320330 at Clinicaltrials.gov.DISCLAIMER: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.PMID:38520670 | DOI:10.1002/pbc.30938

Source: Cancer Control - March 23, 2024 Category: Cancer & Oncology Authors: Emily Greengard Robin Williams Branden Moriarity Xiaowei Liu Charles G Minard Joel M Reid Terrence Fisher Elizabeth Evans Desa Rae Pastore Maurice Zauderer Stephan Voss Elizabeth Fox Brenda J Weigel Source Type: research